14/12/2017 - 09:59 StockMarketWire
Synairgen, the respiratory drug discovery and development company, has revised its collaboration agreement with Pharm...
14/12/2017 - 07:00 RNS
RNS Number: 3339Z Synairgen plc 14 December 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Update on LOXL2 Programme and Collaboration with Pharmaxis 5M payment to Synairgen plus percentage of all future partnering revenues Southampton, UK - 14 December 2017: Synairgen (LSE: SNG), the respiratory drug discovery and development co...
08/11/2017 - 16:31 RNS
RNS Number: 9658V Synairgen plc 08 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Synairgen Plc 1b. Ple...
27/09/2017 - 06:00 RNS
RNS Number: 8967R Synairgen plc 27 September 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2017 Southampton, UK - 27 September 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 J...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment